From Biology to Clinical Practice: Aging and Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 1 SUPPL., 2012, Pages

  Artz, Andrew S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; AGE; AGING; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD ANALYSIS; CANCER SURVIVAL; CLINICAL PRACTICE; COMORBIDITY; CYTOLOGY; DONOR; FEASIBILITY STUDY; FUNCTIONAL ASSESSMENT; GERIATRIC ASSESSMENT; GERIATRIC CARE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA REMISSION; NUTRITION; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; AGING; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855379216     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.11.003     Document Type: Article

References (40)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 2006, 56:106-130.
2. Appelbaum F.R., Gundacker H., Head D.R., et al. Age and acute myeloid leukemia. Blood 2006, 107:3481-3485.
3. Fermand J.P., Levy Y., Gerota J., et al. Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. Blood 1989, 73:20-23.
4. Barlogie B., Alexanian R., Dicke K.A., et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987, 70. 869-772.
5. Clift R.A., Buckner C.D., Appelbaum F.R., et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of 2 irradiation regimens. Blood 1990, 76:1867-1871.
6. Schetelig J., Bornhauser M., Schmid C., et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J Clin Oncol 2008, 26:5183-5191.
7. Aoudjhane M., Labopin M., Gorin N.C., et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005, 19:2304-2312.
8. Yanada M., Emi N., Naoe T., et al. Allogeneic myeloablative transplantation for patients aged 50 years and over. Bone Marrow Transplant 2004, 34:29-35.
9. Estey E., de Lima M., Tibes R., et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007, 109:1395-1400.
10. Farag S.S., Maharry K., Zhang M.J., et al. Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant 2011 June 21, [Epub ahead of print].
11. Gratwohl A., Baldomero H., Frauendorfer K., et al. EBMT activity survey 2004 and changes in disease indication over the past 15 years. Bone Marrow Transplant 2006, 37:1069-1085.
12. Martino R., Iacobelli S., Brand R., et al. Retrospective comparison of reduced intensity conditioning and conventional high dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 2006, 108:836-846.
13. Alyea E.P., Kim H.T., Ho V., et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005, 105:1810-1814.
14. Manton K.G., Corder L., Stallard E. Chronic disability trends in elderly United States populations: 1982-1994. Proc Natl Acad Sci USA 1997, 94:2593-2598.
15. Richa E., Papari M., Allen J., et al. Older age but not donor health impairs allogeneic granulocyte colony-stimulating factor (G-CSF) peripheral blood stem cell mobilization. Biol Blood Marrow Transplant 2009, 15:1394-1399.
16. Kollman C., Howe C.W., Anasetti C., et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001, 98:2043-2051.
17. Lee S.J., Klein J., Haagenson M., et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007, 110:4576-4583.
18. Pulsipher M.A., Chitphakdithai P., Logan B.R., et al. Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood 2009, 114:2606-2616.
19. Uchida N., Wake A., Takagi S., et al. Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases. Biol Blood Marrow Transplant 2008, 14:583-590.
20. Majhail N.S., Brunstein C.G., Tomblyn M., et al. Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol Blood Marrow Transplant 2008, 14:282-289.
21. Cahn J.Y., Labopin M., Schattenberg A., et al. Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years. Acute Leukemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). Leukemia 1997, 11:416-419.
22. Klingemann H.G., Storb R., Fefer A., et al. Bone marrow transplantation in patients aged 45 years and older. Blood 1986, 67:770-776.
23. Przepiorka D., Smith T.L., Folloder J., et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999, 94:1465-1470.
24. Ditschkowski M., Elmaagacli A.H., Trenschel R., et al. Myeloablative allogeneic hematopoietic stem cell transplantation in elderly patients. Clin Transplant 2006, 20:127-131.
25. Artz A.S., Pollyea D.A., Kocherginsky M., et al. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006, 12:954-964.
26. Yancik R., Ganz P.A., Varricchio C.G., et al. Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base. J Clin Oncol 2001, 19:1147-1151.
27. Yancik R., Havlik R.J., Wesley M.N., et al. Cancer and comorbidity in older patients: a descriptive profile. Ann Epidemiol 1996, 6:399-412.
28. Diaconescu R., Flowers C.R., Storer B., et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004, 104:1550-1558.
29. Sorror M.L., Maris M.B., Storer B., et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004, 104:961-968.
30. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
31. Sorror M.L., Maris M.B., Sandmaier B.M., et al. Hematopoietic celltransplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 2005, 23:3819-3829.
32. Artz A.S., Wickrema A., Dinner S., et al. Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008, 14:1209-1216.
33. Sorror M., Storer B., Sandmaier B.M., et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 2008, 112:1992-2001.
34. Gomez-Nunez M., Martino R., Caballero M.D., et al. Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results from the Spanish multicenter prospective trial. Bone Marrow Transplant 2004, 33:477-482.
35. Repetto L., Fratino L., Audisio R.A., et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 2002, 20:494-502.
36. Wedding U., Rohrig B., Klippstein A., et al. Impairment in functional status and survival in patients with acute myeloid leukaemia. J Cancer Res Clin Oncol 2006, 132:665-671.
37. Swanson K., Van Besien K., Extermann M., et al. Geriatric Assessment (GA) may identify vulnerable allogeneic hematopoietic cell transplant (HCT) recipients. Biol Blood Marrow Transplant 2009, 15(Suppl):102-103.
38. Artz A., Swanson K., Kocherginsky M., et al. Features of frailty are surprisingly common in adults 50 years and older undergoing allogeneic hematopoietic cell transplantation (HCT) in the modern era. Biol Blood Marrow Transplant 2011, 17:S302.
39. Armand P., Kim H.T., Cutler C.S., et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007, 109:4586-4588.
40. Fann J.R., Alfano C.M., Burington B.E., et al. Clinical presentation of delirium in patients undergoing hematopoietic stem cell transplantation. Cancer 2005, 103:810-820.